General pharmacological properties, developmental toxicity, and analgesic activity of gambogic acid, a novel natural anticancer agent

In this article, the general pharmacological toxicity of gambogic acid (GA), a new anticancer agent, on the dog cardiovascular and respiratory system and the mouse central nervous system (CNS) were observed. The developmental toxicity and analgesic activities of GA were also investigated in rats and mice. Results showed that GA did not cause any toxic symptoms on blood pressure (i.e., mean arterial pressure), heart rate (HR), and respiratory frequency. However, a high dose of GA showed slight side effects on the mouse CNS. Further, evidence of maternal and developmental toxicity was observed in a dose-dependent manner. The maternal body-weight gain, as well as the birth weights and live birth index, were decreased significantly in the treatment groups. The inhibitory effects of GA on fetal skeletal development were also found. No obvious effects of GA on external alterations and visceral alterations were shown. In the analgesic experiments, GA showed significant analgesic activity in the acetic-acid–induced writhing study in a dose-dependent manner. This mechanism might be related to its anti-inflammation properties.

[1]  P. Dalsenter,et al.  Morinda citrifolia Linn (Noni): in vivo and in vitro reproductive toxicology. , 2009, Journal of ethnopharmacology.

[2]  T. Daniels,et al.  Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoietic cells: functional relevance of iron, the receptor, and reactive oxygen species , 2009, Leukemia.

[3]  Jie Zhao,et al.  Gambogic acid induced tumor cell apoptosis by T lymphocyte activation in H22 transplanted mice. , 2008, International immunopharmacology.

[4]  Yong Yang,et al.  Anti-invasive effect of gambogic acid in MDA-MB-231 human breast carcinoma cells. , 2008, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[5]  Jie Zhao,et al.  Involvement of matrix metalloproteinase 2 and 9 in gambogic acid induced suppression of MDA-MB-435 human breast carcinoma cell lung metastasis , 2008, Journal of Molecular Medicine.

[6]  Jie Zhao,et al.  Inhibition of alpha(4) integrin mediated adhesion was involved in the reduction of B16-F10 melanoma cells lung colonization in C57BL/6 mice treated with gambogic acid. , 2008, European journal of pharmacology.

[7]  John Calvin Reed,et al.  Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins , 2008, Molecular Cancer Therapeutics.

[8]  Q. Qi,et al.  Studies on the toxicity of gambogic acid in rats. , 2008, Journal of ethnopharmacology.

[9]  Mingyao Liu,et al.  Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. , 2008, Cancer research.

[10]  Yong Yang,et al.  Inhibition of glioblastoma growth and angiogenesis by gambogic acid: an in vitro and in vivo study. , 2008, Biochemical pharmacology.

[11]  Yong Yang,et al.  Differential apoptotic induction of gambogic acid, a novel anticancer natural product, on hepatoma cells and normal hepatocytes. , 2007, Cancer letters.

[12]  Q. Qi,et al.  Toxicological studies of gambogic acid and its potential targets in experimental animals. , 2006, Basic & clinical pharmacology & toxicology.

[13]  Q. Qi,et al.  Inhibition of human telomerase reverse transcriptase gene expression by gambogic acid in human hepatoma SMMC-7721 cells. , 2006, Life sciences.

[14]  Rongping Zhang,et al.  Analgesic and antipyretic activities of the aqueous extract of Urtica macrorrhiza in experimental animals. , 2005, Fitoterapia.

[15]  Q. You,et al.  Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. , 2004, Biological & pharmaceutical bulletin.

[16]  Q. You,et al.  Gambogic acid induces apoptosis and regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803 cells. , 2004, Biological & pharmaceutical bulletin.

[17]  Q. You,et al.  General gambogic acids inhibited growth of human hepatoma SMMC-7721 cells in vitro and in nude mice. , 2004, Acta pharmacologica Sinica.

[18]  Q. You,et al.  Gambogic acid inducing apoptosis in human gastric adenocarcinoma SGC-7901 cells , 2004 .

[19]  A. Altamura,et al.  Clinical and psychosocial outcome of patients affected by panic disorder with or without agoraphobia: results from a naturalistic follow-up study , 2002, European Psychiatry.

[20]  S. Cai,et al.  Crystal structure of the pyridine salt of gambogic acid , 2001 .

[21]  K. Terasawa,et al.  General pharmacological properties of Sho-seiryu-to (TJ-19) extracts. , 2001, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[22]  K. Chiba,et al.  Cytotoxic xanthones from Garcinia hanburyi. , 1996, Phytochemistry.

[23]  G. Cordell,et al.  Isogambogic acid and isomorellinol from Garcinia hanburyi , 1993 .

[24]  K. Inoue,et al.  Mechanism of anti-inflammatory action of etodolac. , 1991, Arzneimittel-Forschung.

[25]  K. Hole,et al.  The formalin test in mice: effect of formalin concentration , 1990, Pain.

[26]  K. Nakata,et al.  General pharmacological properties of the potent angiotensin converting enzyme inhibitor rentiapril. , 1987, Arzneimittel-Forschung.

[27]  S. Jouquey,et al.  Release of prostaglandins E and F in an algogenic reaction and its inhibition. , 1980, European journal of pharmacology.

[28]  D. Dubuisson,et al.  The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats , 1977, Pain.

[29]  James G. Wilson,et al.  EMBRYOLOGICAL CONSIDERATIONS IN TERATOLOGY * , 1965, Annals of the New York Academy of Sciences.

[30]  W. Ollis,et al.  The constitution of gambogic acid , 1965 .

[31]  Staples Re,et al.  REFINEMENTS IN RAPID CLEARING TECHNIC IN THE KOH-ALIZARIN RED S METHOD FOR FETAL BONE. , 1964 .